Lung drug faceoff could have limited upside

Share this article:

Talk of a possible head-to-head comparison between Actelion's pulmonary arterial hypertension drug Opsumit and Gilead's Letairis caused enough of a stir that investors punished Actelion's stock Tuesday. Bloomberg reports the talk triggered a 3.1% drop in Actelion's share price, despite the very theoretical nature of the clinical trial.

Bloomberg notes that a trial has varied risks: a Gilead sweep would be bad news for Actelion, which staked its financial independence on Opsumit's potential, whereas an Actelion win would maybe put a minor dent in a business that accounts for less than 5% of Gilead's sales. Bloomberg also notes that any Gilead advantage would be short lived, because the Letairis patent expires in four years.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.